N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl)phenyl)acrylamide | 1428444-25-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl)phenyl)acrylamide
• 英文别名: N-(3-((2-((1-Methyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl)phenyl)acrylamide；N-[3-[[2-[(1-methylpyrazol-4-yl)amino]pyrrolo[2,3-d]pyrimidin-7-yl]methyl]phenyl]prop-2-enamide
• CAS: 1428444-25-0
• 化学式: C₂₀H₁₉N₇O
• 分子量: 373.417
• InChiKey: KSHMJJCPYXRKEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  89.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-chloro-7-(3-nitrobenzyl)-7H-pyrrolo[2,3-d]pyrimidine 在 盐酸 、 N,N-二异丙基乙胺 、 tin(ll) chloride 作用下， 以 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 21.0h， 生成 N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl)phenyl)acrylamide
  参考文献：
  名称：

  [EN] PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
  [FR] DÉRIVÉS DE PYRAZOLO[4,3-C]PYRIDINE COMME INHIBITEURS DE KINASES

  摘要：

  本发明涉及式(I)的化合物，其中X1至X5、Y、ZA、ZB、R和A的含义如描述和权利要求中所述。所述化合物可用作激酶抑制剂，用于治疗或预防免疫、炎症、自身免疫、过敏性疾病和免疫介导疾病。本发明还涉及包括所述化合物的药物组合物以及其作为药物的用途。

  公开号：

  WO2013041605A1

文献信息

• Pyrazolo[4,3-c]Pyridine Derivatives As Kinase Inhibitors
  申请人：Cellzome Limited

  公开号：US20140323504A1

  公开（公告）日：2014-10-30

  The present invention relates to compounds of formula (I) wherein X 1 to X 5 , Y, Z A , Z B , R and A have the meaning as cited in the description and the claims. Said compounds are useful as kinase inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as the use as medicaments.

  本发明涉及式(I)的化合物，其中X1至X5，Y，ZA，ZB，R和A的含义如所述和权利要求中所引用。所述化合物可用作激酶抑制剂，用于治疗或预防免疫、炎症、自身免疫、过敏性疾病和免疫介导疾病。本发明还涉及包括所述化合物的制药组合物以及作为药物的用途。
• PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
  申请人：Cellzome Limited

  公开号：EP2760863A1

  公开（公告）日：2014-08-06
• COMBINATIONS OF BRUTON'S TYROSINE KINASE INHIBITORS AND CYP3A4 INHIBITORS
  申请人：PHARMACYCLICS LLC

  公开号：US20160022683A1

  公开（公告）日：2016-01-28

  Combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, with CYP3A4 inhibitors are provided. Also provided are methods of treating cancers, and autoimmune disorders by administering combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-4((R)-3-(4-amino-3-(4-phenoxyphenyl)-1 H-pyrazolo[3, 4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, and CYP3A4 inhibitors.
• BTK INHIBITOR COMBINATIONS AND DOSING REGIMEN
  申请人：PHARMACYCLICS LLC

  公开号：US20170360796A1

  公开（公告）日：2017-12-21

  Disclosed herein are methods and combination dosing regimen of administering a combination of a BTK inhibitor (e.g. ibrutinib) and an anti-CD20 therapeutic agent for the treatment of a hematologic malignancy. In one aspect is a combination dosing regimen for the treatment of a hematologic malignancy in a subject in need thereof comprising a first phase and a second phase, wherein the first phase is an administration of a BTK inhibitor as a single-agent treatment for a first extended period of time, and the second phase is an administration of a combination of the BTK inhibitor and an anti-CD20 therapeutic agent for a second extended period of time. In one embodiment, the first extended period of time is a period of up to 90 days.
• [EN] PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLO[4,3-C]PYRIDINE COMME INHIBITEURS DE KINASES
  申请人：CELLZOME LTD

  公开号：WO2013041605A1

  公开（公告）日：2013-03-28

  The present invention relates to compounds of formula (I) wherein X1 to X5, Y, ZA, ZB, R and A have the meaning as cited in the description and the claims. Said compounds are useful as kinase inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically- mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as the use as medicaments.

  本发明涉及式(I)的化合物，其中X1至X5、Y、ZA、ZB、R和A的含义如描述和权利要求中所述。所述化合物可用作激酶抑制剂，用于治疗或预防免疫、炎症、自身免疫、过敏性疾病和免疫介导疾病。本发明还涉及包括所述化合物的药物组合物以及其作为药物的用途。